Litcius/Paper detail

Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial

P. Nilsson, Adalsteinn Gunnlaugsson, L. Beckman, Anders Widmark, Per Fransson, Morten Hoyer, Magnus Lagerlund, Jon Kindblom, Bengt Johansson, Kirsten Björnlinger, Claes Ginman, Martha Olsson, Måns Agrup, Elisabeth Kjellén, Björn Zackrisson, Björn Tavelin, Lars G. Franzén, Harald Anderson, Camilla Thellenberg Karlsson

2026The Lancet Oncology7 citationsDOI

Topics & Concepts

Prostate cancerMedicineRadiation therapyOncologyInternal medicineCancerClinical trialRadiologyExternal beam radiotherapyProstatectomyPhase (matter)Phases of clinical researchProstateGynecologyDose fractionationMEDLINEProstate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchAdvanced Radiotherapy Techniques
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial | Litcius